Background: In the era of genome-guided personalized cancer treatment, it is important to understand genomic changes of tumors caused by chemotherapy. Here, we evaluated whether adjuvant FOLFOX ...chemotherapy modifies the mutational profile of recurrent colorectal cancers (CRC). Material and Methods: Whole exome sequencing was performed on primary CRC, untreated metastasis, and recurrent tumors following adjuvant FOLFOX chemotherapy resected from the same patients. We selected patients whose untreated metastasis and recurrent tumors occurred in the same organ to remove the influences by difference of metastatic site. The somatic mutation profiles were compared between patient-matched tumor samples. Results: Four CRC patients with appropriate tumor samples were analyzed. There was no significant differences in the number of mutations, the mutation spectrum, and the copy number changes in individual patients. The genomic signature resulting from L-OHP exposure (G>T/C>A, T>AIA>T transversions) was not increased after FOLFOX chemotherapy. Overlaps of the SNVs and indels remained 26-65% of each tumor samples between patient-matched tumor samples. One patient harbored AKT1 E17K mutation in the recurrent tumor, while PIK3CA E542K and E88Q mutations were detected in the primary and untreated metastasis. The genes related to intracellular Ca2+ homeostasis were enriched among post-FOLFOX unique mutated genes. Conclusion: Our data suggests adjuvant FOLFOX chemotherapy does not produce gene alterations in recurrent cotorectal tumors. The mutational discordance between patient-matched tumor samples are likely to be derived from tumor heterogeneity and clonal selection by the chemotherapy. These findings facilitate the elucidation of chemo-resistance and development of new treatment strategies.
Glomus tumours are relatively rare in the head and neck. We present a glomus tumour of the nasal cavity and paranasal sinuses in a 55-year-old man and describe the CT appearances of this tumour and ...its histopathology.
PDF
